Activity

Exhaustion of stratospheric ozone found at a height of 10-30 km around the world causes the solar UV-B (280-320 nm) radiation to penetrate through the atmosphere more, and thus to reach the Earth’s surface quicker. The protective ozone layer gets damaged by human activities constantly, and the increasing levels of UV radiation present threats to all life forms, plants, animals, and even microorganisms. However, the studies conducted on the effects of UV radiation on plants, and especially forest trees, are rather limited. In this study, it was aimed to identify the effects of UV-B radiation on some germination and seedling characteristics of Anatolian black pine seeds. Within the scope of the study, seeds were exposed to UV-B radiation for 5, 10, 20, 30, 40, 50, and 60 min for germination experiments; and the germination speed (GS) was calculated as the ratio of the germinated seeds to the solid seeds at the end of the 7th day, whereas the germination percentage (GP) was calculated as the ratio of the germinat the end of 7-h application, and that even the decrease in the RP character, which was the least affected by the 7-h UV-B application, was above 50%.

Chronic neutrophilic leukemia (CNL) is a rare myeloproliferative neoplasm (MPN) characterized by oncogenic driver mutations in colony-stimulating factor 3 receptor (CSF3R). Due in large part to the rarity of the disease and dearth of clinical trials, there is currently no standard of care for CNL. Available therapies range from conventional oral chemotherapy to targeted JAK inhibitors to hematopoietic stem cell transplant (HSCT), the latter representing the only potentially curative modality. For this reason, coupled with CNL’s typically aggressive clinical course, allogeneic HSCT remains the primary recommended therapy for eligible patients. For ineligible patients, a number of nontransplant therapies have been evaluated in limited trials. These agents may additionally be considered “bridging” therapies pre-transplant in order to control myeloproliferation and alleviate symptoms. Historically, the most commonly utilized first-line agent has been hydroxyurea, though most patients ultimately require second (cently, ruxolitinib, a JAK1/2 inhibitor targeting JAK-STAT signaling downstream from CSF3R, has emerged as a potentially promising new candidate for the treatment of CNL. Increasingly robust data support the clinical efficacy, with associated variable reductions in allele burden, and tolerability of ruxolitinib in patients with CNL, particularly those carrying the CSF3RT618I mutation. Similar to conventional nontransplant strategies, however, no disease-modifying or survival benefits have been demonstrated. While responses to JAK-STAT inhibition in CNL have not been uniform, data are sufficient to recommend consideration of ruxolitinib in the therapeutic repertory of CNL. There remains a major unmet need for prospective trials with investigational therapies in CNL.

This review summarizes the burden of diabetes in South Asian populations and reviews recent evidence for diabetes prevention through lifestyle modification among South Asians worldwide. We indicate important gaps in the current literature and point to opportunities for additional research in this area.

Randomized, controlled, efficacy studies and implementation research show that lifestyle intervention can be an effective, cost-effective, and feasible method for reducing diabetes risk, improving cardiometabolic health, and improving lifestyle behaviors in South Asian populations, a population at high diabetes risk and elevated rates of diabetes risk factors. Additional research is needed to address diabetes risk reduction in normal-weight South Asians and individuals with impaired fasting glucose; improve community-level implementation, individual uptake, and dissemination of proven programs; and assess long-term outcomes of interventions.

Randomized, controlled, efficacy studies and implementation research show that lifestyle intervention can be an effective, cost-effective, and feasible method for reducing diabetes risk, improving cardiometabolic health, and improving lifestyle behaviors in South Asian populations, a population at high diabetes risk and elevated rates of diabetes risk factors. Additional research is needed to address diabetes risk reduction in normal-weight South Asians and individuals with impaired fasting glucose; improve community-level implementation, individual uptake, and dissemination of proven programs; and assess long-term outcomes of interventions.Lysosome-targetable selenium-doped carbon nanodots (Lyso-Se-CDs) that can efficiently scavenge lysosomal •OH in living cells and mice were designed in this research. Se-CDs with redox-responsive fluorescence (λex = 379 nm, λem = 471 nm, quantum yield = 7.1%) were initially synthesized from selenocystine by a facile hydrothermal method, followed by the surface modification with morpholine, a lysosome targeting moiety. The as-synthesized Lyso-Se-CDs exhibited excellent colloidal stability, efficient scavenging abilities towards •OH, low biotoxicity, as well as good biocompatibility and lysosome targetability. Due to these desirable properties, Lyso-Se-CDs had been successfully utilized for rescuing cells from elevated lysosomal •OH levels. More importantly, Lyso-Se-CDs efficiently relieved phorbol 12-myristate 13-acetate (PMA) triggered ear inflammation in live mice. These findings reveal that Lyso-Se-CDs are potent candidates for treating •OH-related inflammation.

Chimeric antigen receptor (CAR) T-cell therapy has become the standard of care for children and young adults with relapsed and refractory B-cell acute lymphoblastic leukemia (B-ALL), and it is a highly promising therapy under investigation for adults with relapsed disease. Despite having potentially life-threatening toxicities, such as cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, the benefits of CAR T-cell therapy far outweigh these risks, particularly as increased experience and improved supportive care measures are mitigating these toxicities. CAR T cells can result in complete remission for significant proportion of patients with relapsed and refractory B-ALL and permit them to proceed to potentially curative allogeneic hematopoietic stem cell transplantation (allo-HSCT). selleck chemicals CAR T cells may also be curative by themselves. Herein lie the greatest challenges and questions for clinical investigators, specifically, how are CAR T cells best employed and how do we overcome mechanisms of resistance to them? The primary clinical question is the timing and even the necessity of allo-HSCT.